As we bring demethylating drugs to the clinic, we better know the DICE being cast.
In this issue, Weber and coworkers report that DNA-demethylating drugs alter the transcriptional expression of the cMet proto-oncogene. Abnormal transcription is driven by the antisense promoter of a Line-1 repetitive element present within an intron. The element is a recent addition to the genome and is absent in animal models of cancer.
Lizardi
P M
PM
Department of Pathology, Interdepartmental Computational Biology & Bioinformatics Program, Yale University School of Medicine, New Haven, CT 06520, USA. paul.lizardi@mac.com
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019175:DNA Methylation / Q000187:drug effects* / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D020084:Long Interspersed Nucleotide Elements / Q000235:genetics*; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics*; D000090063:Proto-Oncogene Mas; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*
D000970:Antineoplastic Agents; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D019859:Proto-Oncogene Proteins c-met